发布求助
文献互助 智能选刊 最新文献

Uirusu最新文献

筛选
英文 中文
[Development of an engineered ACE2 decoy for COVID-19 therapy.] [开发用于COVID-19疗法的工程化ACE2诱饵]
Uirusu Pub Date : 2023-01-01 DOI: 10.2222/jsv.73.163
Toru Okamoto, Yumi Itoh, Tatsuya Suzuki
{"title":"[Development of an engineered ACE2 decoy for COVID-19 therapy.]","authors":"Toru Okamoto, Yumi Itoh, Tatsuya Suzuki","doi":"10.2222/jsv.73.163","DOIUrl":"https://doi.org/10.2222/jsv.73.163","url":null,"abstract":"<p><p>It has been passed four years since the pandemic caused by the severe acute respiratory syndrome-2 (SARS-CoV-2) that began in 2019. Since June 2020, we have been working on a project to develop a therapeutic drug using receptor decoys, even though we cannot predict how long the pandemic will last or how long our daily lives will be restricted. This receptor decoy utilizes Angiotensin-converting enzyme 2 (ACE2), which is the receptor for SARS-CoV-2, and involves introducing mutations that enhance its binding ability with the spike protein of SARS-CoV-2. This high-affinity ACE2, acting as a decoy protein, is a strategy to inhibit viral infection and to expect therapeutic effects by replacing the endogeneous ACE2 that SARS-CoV-2 binds to with ACE2 decoy. This paper introduces the development of ACE2 decoys that have progressed through collaborative research with many researchers outside the field of virology.</p>","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"73 2","pages":"163-172"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uirusu Pub Date : 2023-01-01 DOI: 10.2222/jsv.73.63
{"title":"","authors":"","doi":"10.2222/jsv.73.63","DOIUrl":"https://doi.org/10.2222/jsv.73.63","url":null,"abstract":"","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"73 1","pages":"63-66"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Identification of a human parechovirus receptor; MYADM]. [人类帕氏病毒受体的鉴定；MYADM]。
Uirusu Pub Date : 2023-01-01 DOI: 10.2222/jsv.73.183
Kanako Watanabe, Masahiro Fujii
{"title":"[Identification of a human parechovirus receptor; MYADM].","authors":"Kanako Watanabe, Masahiro Fujii","doi":"10.2222/jsv.73.183","DOIUrl":"https://doi.org/10.2222/jsv.73.183","url":null,"abstract":"","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"73 2","pages":"183-188"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Identification of new host factors supporting the human papillomavirus life cycle]. [确定支持人类乳头瘤病毒生命周期的新宿主因素]。
Uirusu Pub Date : 2023-01-01 DOI: 10.2222/jsv.73.189
Yoshiyuki Ishii, Seiichiro Mori, Iwao Kukimoto
{"title":"[Identification of new host factors supporting the human papillomavirus life cycle].","authors":"Yoshiyuki Ishii, Seiichiro Mori, Iwao Kukimoto","doi":"10.2222/jsv.73.189","DOIUrl":"https://doi.org/10.2222/jsv.73.189","url":null,"abstract":"","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"73 2","pages":"189-198"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[RNA Virus Pathogenicity, Evolution, and Intrapopulation Interaction]. [RNA 病毒的致病性、进化和种群内相互作用]。
Uirusu Pub Date : 2023-01-01 DOI: 10.2222/jsv.73.95
Yuta Shirogane
{"title":"[RNA Virus Pathogenicity, Evolution, and Intrapopulation Interaction].","authors":"Yuta Shirogane","doi":"10.2222/jsv.73.95","DOIUrl":"https://doi.org/10.2222/jsv.73.95","url":null,"abstract":"<p><p>Measles virus (MeV), the causative agent of measles, can persist in the brain and cause a fatal neurodegenerative disease, subacute sclerosing panencephalitis (SSPE). Because wild-type MeV is not neurotropic, the virus is thought to evolve and acquire neuropathogenicity to cause SSPE. Our recent studies have shown that MeV acquires hyperfusogenic mutations in the fusion (F) gene that confer the ability to use cell adhesion molecule 1 (CADM1) and CADM2 as cis-acting receptor mimicking molecules and allow MeV to spread in neurons. Furthermore, under these conditions, multiple MeV genomes, rather than a single one, are likely to be transmitted transsynaptically between neurons through cell-cell fusion. Therefore, F proteins encoded by different genomes are co-expressed in infected cells, and positive and negative functional interactions between them can occur. These interactions determine the ability of the virus to spread in neurons as a population. In this article, we describe our studies to understand the mechanism by which MeV acquires neuropathogenicity in SSPE.</p>","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"73 1","pages":"95-104"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Changes in rotavirus epidemic strains]. [轮状病毒流行株的变化]。
Uirusu Pub Date : 2023-01-01 DOI: 10.2222/jsv.73.33
Yoshiki Fujii
{"title":"[Changes in rotavirus epidemic strains].","authors":"Yoshiki Fujii","doi":"10.2222/jsv.73.33","DOIUrl":"https://doi.org/10.2222/jsv.73.33","url":null,"abstract":"<p><p>Rotavirus is a major cause of gastroenteritis in infants and is widely prevalent throughout the world regardless of the hygienic environment. However, it is not easy to understand the overall picture of rotavirus epidemic because of the great variety of genotypes and the large inter-seasonal and regional differences in the prevalent strains. Fortunately, the rotavirus vaccines now widely used around the world are highly effective and safe. The number of rotavirus gastroenteritis cases is declining dramatically, especially in high-income countries. In Japan, rotavirus vaccines have been included in the routine vaccination program since October 2020. Additionally, the impact of the SARS-CoV-2 pandemic control measures on the rotavirus epidemic was also very significant. These synergistic effects have resulted in few rotavirus outbreaks in recent years. Nevertheless, rotavirus is unlikely to be completely eradicated, and indeed a small number of sporadic cases continue to be reported. It will continue to be important to maintain high vaccination coverage and to continuously investigate prevalent strains. This review will provide an overview of the rotavirus epidemic situation in Japan and abroad. Annual changes in domestic epidemic strains that have been revealed by steady research to date will also be presented.</p>","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"73 1","pages":"33-44"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[BSL-4 facility and New virus research in Japan]. [BSL-4设施和日本的新病毒研究]。
Uirusu Pub Date : 2022-01-01 DOI: 10.2222/jsv.72.1
Jiro Yasuda
{"title":"[BSL-4 facility and New virus research in Japan].","authors":"Jiro Yasuda","doi":"10.2222/jsv.72.1","DOIUrl":"https://doi.org/10.2222/jsv.72.1","url":null,"abstract":"<p><p>Viral hemorrhagic fevers such as Ebola virus disease, Marburg disease, Lassa fever, and Crimean-Congo hemorrhagic fever are infectious diseases that can cause severe, life-threatening illness. At present, there are only few licensed vaccines and antiviral drugs for these viral hemorrhagic fevers. The viruses which cause these viral hemorrhagic fevers are classified as BSL-4 pathogens and can be handled only in BSL-4 containment laboratories. Therefore, to develop the vaccines and treatments for these diseases, BSL-4 facility is essential. However, the BSL-4 facility available for the basic or applied research using infectious BSL-4 pathogens has not been established in Japan so far. In July 2021, the construction of BSL-4 facility was completed at the campus of Nagasaki University. After the preparation for the full operation, the facility will be approved by the Minister of Health, Labour and Welfare as a BSL-4 facility. Here, I introduce the BSL-4 facility project of Nagasaki University and state the contributions of the BSL-4 facility to research and development.</p>","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"72 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71415853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Digital transformation of COVID-19 research]. 【新冠肺炎研究的数字化转型】。
Uirusu Pub Date : 2022-01-01 DOI: 10.2222/jsv.72.39
Hyeongki Park, Joo Hyeon Woo, Shoya Iwanami, Shingo Iwami
{"title":"[Digital transformation of COVID-19 research].","authors":"Hyeongki Park,&nbsp;Joo Hyeon Woo,&nbsp;Shoya Iwanami,&nbsp;Shingo Iwami","doi":"10.2222/jsv.72.39","DOIUrl":"https://doi.org/10.2222/jsv.72.39","url":null,"abstract":"<p><p>In a current life sciences research, we are in an era in which advanced technology emerging and utilize big data. Data-driven approaches such as machine learnings play an important role to analyze these datasets. However, limited clinical (time-course) datasets are available for infectious diseases, cancer, and other diseases. Especially in the case of emerging infectious disease outbreaks, clinical data obtained from a limited number of cases must be used to develop treatment strategies and public health policies. This means that many clinical data are not big data, which often makes the application of data-driven approaches difficult. In this paper, we mainly apply a mathematical model-based approach to the clinical data of COVID-19 and discuss how biologically important information can be extracted from the limited data and how they can benefit society.</p>","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"72 1","pages":"39-46"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71415856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[South American Hemorrhagic Fever viruses and the cutting edge of the vaccine and antiviral development]. [南美出血热病毒与疫苗和抗病毒药物开发的前沿]。
Uirusu Pub Date : 2022-01-01 DOI: 10.2222/jsv.72.7
Meion Lee, Takaaki Koma, Masaharu Iwasaki, Shuzo Urata
{"title":"[South American Hemorrhagic Fever viruses and the cutting edge of the vaccine and antiviral development].","authors":"Meion Lee,&nbsp;Takaaki Koma,&nbsp;Masaharu Iwasaki,&nbsp;Shuzo Urata","doi":"10.2222/jsv.72.7","DOIUrl":"https://doi.org/10.2222/jsv.72.7","url":null,"abstract":"<p><p>South American Hemorrhagic Fever is caused by the Arenavirus, which belong to the Family Arenaviridae, genus mammarenavirus, infection at South America. South American Hemorrhagic Fever includes 1. Argentinian Hemorrhagic fever caused by Junin virus, 2. Brazilian hemorrhagic fever caused by Sabia virus, 3. Venezuelan Hemorrhagic fever caused by Guanarito virus, 4. Bolivian Hemorrhagic fever caused by Machupo virus, and 5. Unassigned hemorrhagic fever caused by Chapare virus. These viruses are classified in New World (NW) Arenavirus, which is different from Old World Arenavirus (ex. Lassa virus), based on phylogeny, serology, and geographic differences. In this review, the current knowledge of the biology and the development of the vaccines and antivirals of NW Arenaviruses which cause South American Hemorrhagic Fever will be described.</p>","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"72 1","pages":"7-18"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71415862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infectivity-enhancing antibodies against SARS-CoV-2 抗SARS-CoV-2的增强感染抗体
Uirusu Pub Date : 2022-01-01 DOI: 10.33611/trs.2021-021
Yafei Liu, Yukoh Nakazaki, Hisashi Arase
{"title":"Infectivity-enhancing antibodies against SARS-CoV-2","authors":"Yafei Liu, Yukoh Nakazaki, Hisashi Arase","doi":"10.33611/trs.2021-021","DOIUrl":"https://doi.org/10.33611/trs.2021-021","url":null,"abstract":"","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69456700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信